p shp2  (Cell Signaling Technology Inc)

Journal: PLOS One

Article Title: NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-κB/PTEN Signaling

doi: 10.1371/journal.pone.0341816

Figure Lengend Snippet: NFIC promotes OGN and PTEN expression while inhibiting NF-κB, SHP2, and phosphorylated SHP2 expression. A: Western blot analysis of NFIC, OGN, p-NF-κB, SHP2, and p-SHP2 protein bands in six groups (NFIC-NC, NFIC-OE, NF-κB NC, NF-κB NC, PHPS1 NC, PHPS1 OE), with statistical analysis of relative protein expression levels. B: Western blot analysis of PTEN and HEY1 protein bands in six groups, along with statistical analysis of relative protein expression levels. Data are expressed as mean ± standard deviation. N = 3, P < 0.05 indicates statistically significant difference, * P < 0.05; ** P < 0.01; nsP > 0.05.

Article Snippet: The membranes were blocked in TBST buffer containing 5% skimmed milk at 37°C for 2 hours, followed by overnight incubation at 4°C with the following primary antibodies: NFIC (CST, #11911, 1:1000), OGN (CST, #24083, 1:1000), NF-κB (CST, #8242, 1:1000), SHP2 (CST, #3752, 1:1000), p-SHP2 (CST, #13379, 1:1000), PI3K (CST, #4292, 1:1000), AKT (CST, #4060, 1:2000), Cyclin A1 (CST, #4656, 1:2000), Cyclin D1 (CST, #2922, 1:1000), MMP-3 (CST, #14351, 1:1000), and MMP-9 (CST, #3852, 1:1000).

Techniques: Expressing, Western Blot, Standard Deviation

Journal: PLOS One

Article Title: NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-κB/PTEN Signaling

doi: 10.1371/journal.pone.0341816

Figure Lengend Snippet: NFIC promotes OGN and PTEN expression while suppressing NF-κB, SHP2, and phosphorylated SHP2 expression. A: Western blot detection of p-PIK, p-AKT, p-STAT3, GAPDH protein bands, and statistical analysis of relative protein expression levels; B: Western blot detection of Cyclin A1, Cyclin D1, MMP-3, and MMP-9 protein bands in the six groups, and statistical analysis of relative protein expression levels. Data are expressed as mean ± standard deviation. N = 3, P < 0.05 indicates statistically significant difference, * P < 0.05; ** P < 0.01; nsP > 0.05.

Article Snippet: The membranes were blocked in TBST buffer containing 5% skimmed milk at 37°C for 2 hours, followed by overnight incubation at 4°C with the following primary antibodies: NFIC (CST, #11911, 1:1000), OGN (CST, #24083, 1:1000), NF-κB (CST, #8242, 1:1000), SHP2 (CST, #3752, 1:1000), p-SHP2 (CST, #13379, 1:1000), PI3K (CST, #4292, 1:1000), AKT (CST, #4060, 1:2000), Cyclin A1 (CST, #4656, 1:2000), Cyclin D1 (CST, #2922, 1:1000), MMP-3 (CST, #14351, 1:1000), and MMP-9 (CST, #3852, 1:1000).

Techniques: Expressing, Western Blot, Standard Deviation

Journal: PLOS One

Article Title: NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-κB/PTEN Signaling

doi: 10.1371/journal.pone.0341816

Figure Lengend Snippet: NFIC inhibits glioblastoma cell proliferation and invasion, while NF-κB promotes these processes. A: Co-immunoprecipitation (CO-IP) analysis of NFIC and PTEN protein bands in six sample groups; B: CO-IP analysis of OGN and NF-κB protein bands in six sample groups; C: CO-IP analysis of NF-κB and SHP2 protein bands in six sample groups; D: CO-IP analysis of NFIC and OGN protein bands in six sample groups; Data are expressed as mean ± standard deviation. N = 3, P < 0.05 indicates statistically significant difference; * P < 0.05; ** P < 0.01; nsP > 0.05.

Article Snippet: The membranes were blocked in TBST buffer containing 5% skimmed milk at 37°C for 2 hours, followed by overnight incubation at 4°C with the following primary antibodies: NFIC (CST, #11911, 1:1000), OGN (CST, #24083, 1:1000), NF-κB (CST, #8242, 1:1000), SHP2 (CST, #3752, 1:1000), p-SHP2 (CST, #13379, 1:1000), PI3K (CST, #4292, 1:1000), AKT (CST, #4060, 1:2000), Cyclin A1 (CST, #4656, 1:2000), Cyclin D1 (CST, #2922, 1:1000), MMP-3 (CST, #14351, 1:1000), and MMP-9 (CST, #3852, 1:1000).

Techniques: Immunoprecipitation, Co-Immunoprecipitation Assay, Standard Deviation

Journal: PLOS One

Article Title: NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-κB/PTEN Signaling

doi: 10.1371/journal.pone.0341816

Figure Lengend Snippet: NFIC binds to the promoter regions of OGN and PTEN and regulates their transcription, leading to increased expression of these two genes. Immunohistochemical staining results for NFIC, PTEN, OGN, NF-κB, and p-SHP2, along with statistical analysis of staining. Data are presented as mean ± standard deviation. N = 3, P < 0.05 indicates statistically significant difference, *P < 0.05, **P < 0.01.

Article Snippet: The membranes were blocked in TBST buffer containing 5% skimmed milk at 37°C for 2 hours, followed by overnight incubation at 4°C with the following primary antibodies: NFIC (CST, #11911, 1:1000), OGN (CST, #24083, 1:1000), NF-κB (CST, #8242, 1:1000), SHP2 (CST, #3752, 1:1000), p-SHP2 (CST, #13379, 1:1000), PI3K (CST, #4292, 1:1000), AKT (CST, #4060, 1:2000), Cyclin A1 (CST, #4656, 1:2000), Cyclin D1 (CST, #2922, 1:1000), MMP-3 (CST, #14351, 1:1000), and MMP-9 (CST, #3852, 1:1000).

Techniques: Expressing, Immunohistochemical staining, Staining, Standard Deviation

Journal: PLOS One

Article Title: NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-κB/PTEN Signaling

doi: 10.1371/journal.pone.0341816

Figure Lengend Snippet: NFIC promotes OGN and PTEN expression while suppressing NF-κB, SHP2, p-SHP2, PI3K, AKT, Cyclin A1, Cyclin D1, MMP-3, and MMP-9 expression. NF-κB promotes SHP2 expression, while OGN and PTEN inhibit p-SHP2 expression. NFIC suppresses glioma cell proliferation and invasion, whereas NF-κB promotes these processes.

Article Snippet: The membranes were blocked in TBST buffer containing 5% skimmed milk at 37°C for 2 hours, followed by overnight incubation at 4°C with the following primary antibodies: NFIC (CST, #11911, 1:1000), OGN (CST, #24083, 1:1000), NF-κB (CST, #8242, 1:1000), SHP2 (CST, #3752, 1:1000), p-SHP2 (CST, #13379, 1:1000), PI3K (CST, #4292, 1:1000), AKT (CST, #4060, 1:2000), Cyclin A1 (CST, #4656, 1:2000), Cyclin D1 (CST, #2922, 1:1000), MMP-3 (CST, #14351, 1:1000), and MMP-9 (CST, #3852, 1:1000).

Techniques: Expressing

Journal: PLOS One

Article Title: SHP2 improved Late-onset fetal growth restriction via modulating ROS/BRD4/PI3K/YAP/PIGF signaling induced angiogenesis

doi: 10.1371/journal.pone.0342649

Figure Lengend Snippet: A: Boxplot of sample normalization for the FGR dataset GSE147776 ; B: Volcano plot of differentially expressed genes for the FGR dataset GSE147776 ; C: Heatmap of differentially expressed gene clustering for the FGR dataset GSE147776 ; Da: GO enrichment bubble plot of DEGs; Db: GO enrichment bar plot of DEGs; Ea: KEGG enrichment bubble plot of DEGs; Eb: KEGG enrichment lollipop plot of DEGs; F: Scatter plot of BRD4 and KEAP1 correlation; G: Scatter plot of KEAP1 and Nrf2 correlation; H: Heatmap of molecular interactions among BRD4, NOX4, NOX2, Nrf2, SHP2, P53, VEGFR, PI3K, CREB, JNK, and P38; I: Lollipop plot of YAP and effector factor correlations (CREB, VEGF, VEGFR2, SOX9, OCT4, SOX2, Ki-67, Nrf2).

Article Snippet: Rabbit anti-NOX4 antibody, nuclear BRD4 antibody, phospho §-SHP2 antibody, p-PI3K antibody, nuclear YAP antibody, Nrf2 antibody, PIGF antibody, VEGF antibody, HIF1α antibody, OCT4 antibody, SOX2 antibody, and C-Myc antibody were purchased from Wuhan Sanying Biotechnology Co., Ltd. Rabbit secondary antibody, RIPA lysis buffer, and ECL luminescence solution were purchased from Beijing Lanjie Technology Co., Ltd.

Techniques:

Journal: PLOS One

Article Title: SHP2 improved Late-onset fetal growth restriction via modulating ROS/BRD4/PI3K/YAP/PIGF signaling induced angiogenesis

doi: 10.1371/journal.pone.0342649

Figure Lengend Snippet: A: Western blot analysis of NOX4, nuclear BRD4, p-SHP2, p-PI3K, nuclear YAP, Nrf2, and PIGF protein expressions in EPCs in the following six groups: NC group, Model group, Model + JQ-1 group, Model + JQ-1 + PHPS1 group, Model + JQ-1 + PHPS1 + 740Y-P group, and Model + JQ-1 + PHPS1 + 740Y-P + Verteporfin group, GAPDH as the control protein; B: Statistical analysis of relative protein expression levels. N = 3; Data are expressed as mean ± standard deviation; Different lowercase letters on the same column indicate significant differences between groups at P < 0.05, while different uppercase letters indicate significant differences at P < 0.01.

Article Snippet: Rabbit anti-NOX4 antibody, nuclear BRD4 antibody, phospho §-SHP2 antibody, p-PI3K antibody, nuclear YAP antibody, Nrf2 antibody, PIGF antibody, VEGF antibody, HIF1α antibody, OCT4 antibody, SOX2 antibody, and C-Myc antibody were purchased from Wuhan Sanying Biotechnology Co., Ltd. Rabbit secondary antibody, RIPA lysis buffer, and ECL luminescence solution were purchased from Beijing Lanjie Technology Co., Ltd.

Techniques: Western Blot, Control, Expressing, Standard Deviation

Journal: PLOS One

Article Title: SHP2 improved Late-onset fetal growth restriction via modulating ROS/BRD4/PI3K/YAP/PIGF signaling induced angiogenesis

doi: 10.1371/journal.pone.0342649

Figure Lengend Snippet: SHP2 induces endothelial progenitor cell activation by regulating ROS/BRD4 and PI3K/YAP/PIGF, improving late-onset fetal growth restriction.

Article Snippet: Rabbit anti-NOX4 antibody, nuclear BRD4 antibody, phospho §-SHP2 antibody, p-PI3K antibody, nuclear YAP antibody, Nrf2 antibody, PIGF antibody, VEGF antibody, HIF1α antibody, OCT4 antibody, SOX2 antibody, and C-Myc antibody were purchased from Wuhan Sanying Biotechnology Co., Ltd. Rabbit secondary antibody, RIPA lysis buffer, and ECL luminescence solution were purchased from Beijing Lanjie Technology Co., Ltd.

Techniques: Activation Assay

Journal: Frontiers in Pharmacology

Article Title: Antitumor effects of LPM5140276 and its potential combination with SHP2 inhibition in KRAS G12D -mutant cancer

doi: 10.3389/fphar.2025.1554356

Figure Lengend Snippet: Effects of LPM5140276 and/or RMC4550 on the signaling pathways related to cell proliferation, cell-cycle arrest, and apoptosis. (A) In the AsPC-1 cells, p-ERK and p-AKT levels were reduced in a dose-dependent manner 3 h after LPM5140276 treatment. (B) LPM5140276-treated AsPC-1 cells showed downregulated CDK4 and cyclin D1 expression at 3 h, 12 h, 24 h, and 48 h. (C) p-ERK levels decreased from 3 h to 48 h but rebounded at 72 h, while p-AKT levels decreased from 3 h to 24 h and rebounded at 48 h. LPM5140276 treatment upregulated cleaved caspase-3 and cleaved caspase-7 levels from 3 h to 72 h in the AsPC-1 cells. (D) LPM5140276 monotherapy reduced p-ERK level in a concentration-dependent manner but increased p-SHP2 level in the AsPC-1 cells at 3 h. Compared to single-agent treatments, combined administration of RMC4550 and LPM5140276 at increasing concentrations resulted in greater suppression of both p-ERK and p-SHP2 at 3 h.

Article Snippet: Antibodies against Ras (G12D-mutant specific; #14429), SHP2 (#3752), p-SHP2 (#3751), ERK1/2 (#4695), p-ERK1/2 (#4370), AKT (#4691), p-AKT (#4058), CDK4 (#12790), cyclin D1 (#2922), cleaved caspase-3 (#9661), and cleaved caspase-7 (#9491) were purchased from Cell Signaling Technology.

Techniques: Protein-Protein interactions, Expressing, Concentration Assay